论文部分内容阅读
目的 :观察抗癌新药NVB(去甲长春花碱Navelbine) +DDP(顺铂 )联合化疗治疗晚期非小细胞肺癌 (NonsmallcelllungcancerNSCLC)的疗效及毒副反应。方法 :治疗晚期NSCLC 30例。男性 2 3例 ,女性 7例。病理类型 :腺癌 1 8例 ,鳞癌 8例 ,大细胞未分化癌 2例、腺鳞癌 2例 ;ⅢB 期 1 4例 ,Ⅳ期 1 6例。初治2 1例 ,复治 9例。结果 :完全缓解 (CR) 1例 ,部分缓解 (PR) 1 3例 ,稳定 (S) 1 1例 ,进展 (P) 5例 ,总有效率4 6 6 % ,中位缓解期 3 6个月 ,中位生存期 9 2个月。NVB的剂量限制毒性为骨髓抑制。白细胞下降达1 0 0 % ,其中Ⅲ、Ⅳ度为 6 0 % ,重度血色素及血小板下降率相对较低 ,注射局部静脉毒性发生率 2 3 3%。结论 :NVB +DDP联合化疗治疗晚期NSCLC有效率高 ,毒性可以耐受 ,是很好的联合方案 ,值得临床研究。NVB使用时严格按药品使用方法 ,可减少局部静脉毒性发生
OBJECTIVE: To observe the curative effect and toxicity of anti-cancer drug NVB (NVP) combined with DDP (cisplatin) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Thirty patients with advanced NSCLC were treated. There were 23 males and 7 females. Pathological types: 18 cases of adenocarcinoma, 8 cases of squamous cell carcinoma, 2 cases of large cell undifferentiated carcinoma, 2 cases of adenosquamous carcinoma; 14 cases of stage ⅢB, 16 cases of stage Ⅳ. 21 cases of initial treatment, retreatment in 9 cases. Results: Complete remission (CR) in 1 case, partial remission (PR) in 13 cases, stable (S) in 11 cases, progression (P) in 5 cases, total effective rate 46.6%, and median remission 36 months , Median survival 9 2 months. The dose limiting toxicity of NVB is myelosuppression. Leukopenia reached 100%, of which Ⅲ, Ⅳ degrees were 60%, severe hemoglobin and platelet decline was relatively low, local injection of venous toxicity 23.3%. Conclusion: The combination of NVB + DDP and chemotherapy in advanced NSCLC is highly effective and tolerable. It is a good combination and worthy of clinical study. NVB use strictly in accordance with the method of drug use, can reduce the occurrence of local venous toxicity